Selling Sickness

In this hard-hitting indictment of the pharmaceutical industry, Ray Moynihan and Allan Cassels show how drug companies are systematically using their dominating influence in the world of medical science, drug companies are working to widen the very boundaries that define illness. Mild problems are redefined as serious illness, and common complaints are labeled as medical conditions requiring drug treatments. Runny noses are now allergic rhinitis, PMS has become a psychiatric disorder, and hyperactive children have ADD. Selling Sickness reveals how expanding the boundaries of illness and lowering the threshold for treatments is creating millions of new patients and billions in new profits, in turn threatening to bankrupt national healthcare systems all over the world. This Canadian edition includes an introduction placing the issue in a Canadian context and describing why Canadians should be concerned about the problem.

read this book and rage.' Clive Hamilton This remarkable investigation of the Sickness Industry is by two accomplished writers with an incredible story to tell.' Robyn Williams Three decades ago, the head of one of the world's leading drug companies made some remarkably candid comments. Wishing his company was more like the chewing gum maker Wrigley's, the chief executive of Merck said it had long been his dream to make drugs for healthy people, and sell to everyone'. That dream now drives the marketing machinery of one of the most profitable industries on the planet. Using their dominating influence in medical science, drug companies are marketing fear in order to re-define human illness. In alliance with company-friendly doctors and sponsored patient groups, the all-powerful pharmaceutical industry is helping to widen the very definitions of disease, in order to expand markets for its drugs. With compelling clarity, Selling Sickness reveals how the ups and downs of daily life are becoming mental disorders, and common complaints are being transformed into frightening conditions. Shyness is Social Anxiety Disorder, PMS is a psychiatric illness called PMDD, and active children now have ADHD. As more and more ordinary people are turned into patients, drug companies move ever closer to that dream of selling to everyone.

Reveals how widening the boundaries of illness and lowering the threshold for treatments is creating millions of new patients and billions in new profits, in turn threatening to bankrupt national healthcare systems all over the world.

Explaining the innovative, radical, and aggressive approaches towards a more effective and efficient public health care, this definitive guide wraps up the series of seminars, workshops, and publications from CROSSTALKS--Vrije Universiteit Brussel's university and industry network that aims to bridge the gap between the academic and industrial world. This account examines the information gathered from 2005 to 2008 and discusses the contemporary challenges as well as the advances in medicine. Seeking to generate an open dialog about the world of health care, this compilation brings together voices from academic, political, corporate, and patient communities that want to engage in a collaborative exploration of the future of public health care.

Pharmaceutical medicine is very, very big business. The top ten players earned more than $200 billion in 2003. One drug, Pfizer's cholesterol pill Lipitor, had sales of more than $9 billion. This kind of money buys an awful lot of friends among doctors and politicians. Most of those involved in the formulation of public health policy seems happy with the present system. The trouble is that the public is starting to have doubts. There is a growing sense that the vast profits of drug companies and their control of the research agenda might not be that good for our health. Jacky Law takes the reader on a journey through the pharmaceutical business and shows how the public is quite right to be concerned about conventional medicine, as it has developed since the late 1970s. She tells a story of spectacular regulatory failure, phenomenally high prices, betrayal of the public interest and a growing awareness among ordinary people that things could be very different. Sophisticated marketing and public relations, not scientific excellence, have helped corporations to preside unchallenged over matters of life and death. It is time, Law argues, for us to take responsibility for our health, not as passive consumers of pharmaceutical medicine, but as informed citizens.

The Pharmaceutical Studies Reader is an engaging survey of the field that brings together provocative, multi-disciplinary scholarship examining the interplay of medical science, clinical practice, consumerism, and the healthcare marketplace. Draws on anthropological, historical, and sociological approaches to explore the social life of pharmaceuticals with special emphasis on their production, circulation, and consumption Covers topics such as the role of drugs in shaping taxonomies of disease, the evolution of prescribing habits, ethical dimensions of pharmaceuticals, clinical trials, and drug research and marketing in the age of globalization Offers a compelling, contextually-rich treatment of the topic that exposes readers to a variety of approaches, ideas, and frameworks Provides an accessible introduction for readers with no previous background in this area